← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT04992572

NCT04992572 Study Comparing Local/ MAC Anesthesia in Lumbar Decompression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04992572
Status Recruiting
Phase EARLY_Phase 1
Sponsor Stanford University
Condition Lumbar Spinal Stenosis
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2021-12-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 95 Years
Study Type INTERVENTIONAL
Interventions
Propofol InjectionLidocaine Hydrochloride, Injectable

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 100 participants in total. It began in 2021-12-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Explore efficacy, complications, and other factors associated with anaesthetic choice- To evaluate the efficacy of local + MAC as an alternative anesthetic to general anesthesia and to analyze patients' outcomes and experiences.

Eligibility Criteria

Inclusion Criteria: Patients with lumbar stenosis to be decompressed over 1-3 segments * Ages 40-95 * Appropriate for general anesthesia Exclusion Criteria: * Planned significant nerve root retraction * Previous fusion operation * Unable to comply with follow up * Patients with daily morphine equivalents or more 100mg * Patients with a known hypersensitivity to propofol or any of DIPRIVAN Injectable Emulsion components. * Patients with allergies to eggs, egg products, soybeans or soy products.

Contact & Investigator

Central Contact

Sarah Miller, MAS

✉ sarahmi@stanford.edu

📞 650-725-7984

Principal Investigator

Todd Alamin, MD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT04992572 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 95 Years, studying Lumbar Spinal Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT04992572 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT04992572 currently recruiting?

Yes, NCT04992572 is actively recruiting participants. Contact the research team at sarahmi@stanford.edu for enrollment information.

Where is the NCT04992572 trial being conducted?

This trial is being conducted at Redwood City, United States, Redwood City, United States.

Who is sponsoring the NCT04992572 clinical trial?

NCT04992572 is sponsored by Stanford University. The principal investigator is Todd Alamin, MD at Stanford University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology